Wall Street Zen cut shares of Veru (NASDAQ:VERU – Free Report) from a hold rating to a sell rating in a research report released on Saturday.
Other equities research analysts have also issued reports about the stock. Oppenheimer dropped their price objective on shares of Veru from $25.00 to $24.00 and set an “outperform” rating on the stock in a report on Friday, May 15th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $25.00 target price on shares of Veru in a research note on Thursday, June 4th. Finally, Weiss Ratings upgraded Veru from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 5th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $24.50.
Check Out Our Latest Analysis on Veru
Veru Stock Performance
Veru (NASDAQ:VERU – Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.02. On average, analysts predict that Veru will post -1.07 EPS for the current year.
Institutional Trading of Veru
Hedge funds and other institutional investors have recently made changes to their positions in the business. Royal Bank of Canada lifted its position in shares of Veru by 69.3% in the first quarter. Royal Bank of Canada now owns 12,239 shares of the company’s stock worth $27,000 after purchasing an additional 5,008 shares in the last quarter. Northwestern Mutual Wealth Management Co. bought a new position in Veru in the third quarter valued at $38,000. XTX Topco Ltd acquired a new stake in Veru in the 2nd quarter valued at $49,000. ADAR1 Capital Management LLC acquired a new stake in Veru in the 4th quarter valued at $75,000. Finally, Blair William & Co. IL increased its stake in Veru by 26.3% in the 4th quarter. Blair William & Co. IL now owns 48,000 shares of the company’s stock valued at $103,000 after buying an additional 10,000 shares during the last quarter. 47.16% of the stock is currently owned by institutional investors and hedge funds.
About Veru
Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.
The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.
See Also
- Five stocks we like better than Veru
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.
